How this Stanford biotech spinout plans to quickly boost gene therapy
The Peninsula startup snared a $45 million Series A round but plans to start a clinical trial in sickle cell disease as early as the first half of next year.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Biotechnology | Clinical Trials | Gene Therapy | Genetics | Health Management | Pharmaceuticals | Sickle Cell Anemia